INS and cancer: With close collaborations between academia and industry, recombinant IFNα2 became the first human immunotherapeutic approved by the US Food and Drug Administration (FDA) for cancer and, other than insulin, the first FDA-approved pharmaceutical product produced by recombinant DNA technology (30).